The indolent nature of low-grade IDH-mutant gliomas renders these tumors difficult to generate patient-derived cell lines that proliferate in vitro or in xenograft models, and engineered approaches that utilize exogenous mutant IDH expression are limited in their ability to fully capture the genetic and epigenetic landscape observed in human tumors. The gene discussed is IDH1; the disease is glioma.